Immuno Onocology Training

Immuno Onocology Training 28. Oktober 2016

The recording of the lecture by Prof. Zielinski can be seen by following this link: cecog.medroom.at

ASCO –GI Symposium 2017

Highlights from ASCO –GI Symposium 2017

The Gastrointestinal Cancers Symposium was hold in San Francisco from 19th of January till 21st of January 2017. A summary report (in German) of Univ. Prof. Wolfgang Eisterer and Univ. Prof Dr. Gerald Prager can be recalled following the link: cecog.medroom.at

ESMO 2014

Bevacizumab in HER2 negative metastatic breast cancer

C.Zielinski comments on two milestone phase 3 trials, TANIA and IMELDA, analysing efficacy and safety of continuing vs stopping bev in HER2 neg met breast cancer.

ESMO 2013

Are the costs of clinical trials higher than standard care?

C. Zielinski comments on a study evaluating differences in costs between patients in clinical trials and patients receiving standard of care, anticipating possible future savings

ASCO 2013

„Ten years of tamoxifen help reduce breast cancer recurrence”

Prof. Zielinski shares his comments on findings from the aTTom study presented at ASCO 2013 Annual Meeting

Kurier 2013

KURIER (Vienna) , 27th November 2013:

Report about the CECOG/MedAustron Symposium in Wiener Neustadt

Volle Strahlendosis gegen den Tumor

Article 2013

Summary of a consensus conference at the Research Center MedAustron, 21 11, 2013,

Carried out carried out by MedAustron (Univ.-Prof. Dr. Ramona Mayer) in collaboration with Central European Cooperative Oncology Group (CECOG, President Univ.-Prof. Dr. Dr.h.c. Christoph Zielinski) and their affiliated scientists.

 Article PDF (In German)

ESMO 2012

Cancer care in austerity times

How to improve equal access to quality cancer care.

Genomics of Breast Cancer

Triple Negative Breast Cancer

Cost of personalized medicine

How does it affect the practice of medical oncologists?

Age still discriminatory when treating women with breast cancer?

Prof. Zielinski highlights the need to guarantee optimal breast cancer treatment irrespective of the patient’s age as well as the influence of pregnancy after cancer.

Are the costs of clinical trials higher than standard of care?

Prof. Zielinski comments on a study evaluating differences in costs between patients in clinical trials and patients receiving standard of care, anticipating possible future savings.